Legend Biotech (LEGN) Operating Leases (2019 - 2025)

Legend Biotech (LEGN) has 7 years of Operating Leases data on file, last reported at $87.2 million in Q4 2025.

• In Q4 2025, Operating Leases rose 95.52% year-over-year to $87.2 million; the TTM figure through Dec 2025 stood at $87.2 million (up 95.52% YoY), while the FY2025 annual figure was $87.2 million, up 95.52% from the prior year.
• Operating Leases retreated to $87.2 million in Q4 2025, from $88.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $88.1 million in Q3 2025 and bottomed at $2.5 million in Q4 2021.
• A 5-year average of $48.5 million and a median of $44.5 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases decreased 25.76% — and 2022, when it soared 842.57%.
• Year by year, Operating Leases stood at $2.5 million in 2021, then soared by 842.57% to $23.6 million in 2022, then jumped by 87.14% to $44.2 million in 2023, then advanced by 0.98% to $44.6 million in 2024, then soared by 95.52% to $87.2 million in 2025.
• The last three Operating Leases figures came in at $87.2 million (Q4 2025), $88.1 million (Q3 2025), and $71.7 million (Q2 2025), per Business Quant data.

Peer Comparison